212 related articles for article (PubMed ID: 33902956)
1. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria.
Ling S; Feng T; Zhan Q; Duan X; Jiang G; Shen T; Shan Q; Xu S; Ye Q; Liu P; Cen B; Zheng S; Xu X
Ann Transl Med; 2020 Feb; 8(4):80. PubMed ID: 32175373
[TBL] [Abstract][Full Text] [Related]
3. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma.
Xu SL; Zhang YC; Wang GY; Yang Q; Liu B; Zhang J; Li H; Wang GS; Yang Y; Chen GH
Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):674-681. PubMed ID: 27825633
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Geissler EK; Schnitzbauer AA; Zülke C; Lamby PE; Proneth A; Duvoux C; Burra P; Jauch KW; Rentsch M; Ganten TM; Schmidt J; Settmacher U; Heise M; Rossi G; Cillo U; Kneteman N; Adam R; van Hoek B; Bachellier P; Wolf P; Rostaing L; Bechstein WO; Rizell M; Powell J; Hidalgo E; Gugenheim J; Wolters H; Brockmann J; Roy A; Mutzbauer I; Schlitt A; Beckebaum S; Graeb C; Nadalin S; Valente U; Turrión VS; Jamieson N; Scholz T; Colledan M; Fändrich F; Becker T; Söderdahl G; Chazouillères O; Mäkisalo H; Pageaux GP; Steininger R; Soliman T; de Jong KP; Pirenne J; Margreiter R; Pratschke J; Pinna AD; Hauss J; Schreiber S; Strasser S; Klempnauer J; Troisi RI; Bhoori S; Lerut J; Bilbao I; Klein CG; Königsrainer A; Mirza DF; Otto G; Mazzaferro V; Neuhaus P; Schlitt HJ
Transplantation; 2016 Jan; 100(1):116-25. PubMed ID: 26555945
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
[TBL] [Abstract][Full Text] [Related]
8. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
Yanik EL; Chinnakotla S; Gustafson SK; Snyder JJ; Israni AK; Segev DL; Engels EA
Liver Transpl; 2016 May; 22(5):627-34. PubMed ID: 26784951
[TBL] [Abstract][Full Text] [Related]
9. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.
Menon KV; Hakeem AR; Heaton ND
Aliment Pharmacol Ther; 2013 Feb; 37(4):411-9. PubMed ID: 23278125
[TBL] [Abstract][Full Text] [Related]
11. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Schnitzbauer AA; Filmann N; Adam R; Bachellier P; Bechstein WO; Becker T; Bhoori S; Bilbao I; Brockmann J; Burra P; Chazoullières O; Cillo U; Colledan M; Duvoux C; Ganten TM; Gugenheim J; Heise M; van Hoek B; Jamieson N; de Jong KP; Klein CG; Klempnauer J; Kneteman N; Lerut J; Mäkisalo H; Mazzaferro V; Mirza DF; Nadalin S; Neuhaus P; Pageaux GP; Pinna AD; Pirenne J; Pratschke J; Powel J; Rentsch M; Rizell M; Rossi G; Rostaing L; Roy A; Scholz T; Settmacher U; Soliman T; Strasser S; Söderdahl G; Troisi RI; Turrión VS; Schlitt HJ; Geissler EK
Ann Surg; 2020 Nov; 272(5):855-862. PubMed ID: 32889867
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma.
Campsen J; Zimmerman MA; Trotter JF; Wachs M; Bak T; Mandell S; Kam I
Expert Opin Pharmacother; 2007 Jun; 8(9):1275-82. PubMed ID: 17563262
[TBL] [Abstract][Full Text] [Related]
14.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
Kneteman NM; Oberholzer J; Al Saghier M; Meeberg GA; Blitz M; Ma MM; Wong WW; Gutfreund K; Mason AL; Jewell LD; Shapiro AM; Bain VG; Bigam DL
Liver Transpl; 2004 Oct; 10(10):1301-11. PubMed ID: 15376305
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
Liang W; Wang D; Ling X; Kao AA; Kong Y; Shang Y; Guo Z; He X
Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma.
Zhang L; Liu P; Zhuang L; Ling S; Zhan Q; Zhou W; Su R; Yin L; Que Q; Hong J; Bao J; Shao C; Cai J; Zheng S; Xu X
Mol Biomed; 2024 Mar; 5(1):9. PubMed ID: 38461206
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial.
Lee KW; Kim SH; Yoon KC; Lee JM; Cho JH; Hong SK; Yi NJ; Han SS; Park SJ; Suh KS
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33053849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
